M&T Bank Corp Increases Holdings in Stryker Corporation $SYK

M&T Bank Corp raised its stake in shares of Stryker Corporation (NYSE:SYK) by 10.0% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 47,160 shares of the medical technology company’s stock after buying an additional 4,287 shares during the period. M&T Bank Corp’s holdings in Stryker were worth $16,575,000 as of its most recent SEC filing.

A number of other hedge funds have also added to or reduced their stakes in the stock. Czech National Bank raised its position in shares of Stryker by 3.9% during the 4th quarter. Czech National Bank now owns 90,755 shares of the medical technology company’s stock valued at $31,898,000 after acquiring an additional 3,366 shares during the last quarter. Davis R M Inc. grew its holdings in shares of Stryker by 1.8% in the 3rd quarter. Davis R M Inc. now owns 138,732 shares of the medical technology company’s stock valued at $51,285,000 after buying an additional 2,512 shares during the period. Terra Alpha Investments LLC acquired a new position in shares of Stryker in the 3rd quarter valued at $1,216,000. Kepler Cheuvreux Suisse SA acquired a new position in shares of Stryker in the 3rd quarter valued at $27,952,000. Finally, Daymark Wealth Partners LLC grew its holdings in shares of Stryker by 436.0% in the 4th quarter. Daymark Wealth Partners LLC now owns 45,863 shares of the medical technology company’s stock valued at $16,119,000 after buying an additional 37,307 shares during the period. 77.09% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Stryker

In related news, Director Ronda E. Stryker sold 250,000 shares of Stryker stock in a transaction on Wednesday, February 4th. The shares were sold at an average price of $362.92, for a total value of $90,730,000.00. Following the sale, the director owned 2,457,331 shares of the company’s stock, valued at approximately $891,814,566.52. This trade represents a 9.23% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 4.60% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on the stock. Sanford C. Bernstein set a $410.00 price target on shares of Stryker in a report on Friday. Robert W. Baird set a $385.00 price target on shares of Stryker in a report on Friday. Citigroup decreased their price target on shares of Stryker from $420.00 to $385.00 and set a “buy” rating for the company in a report on Tuesday, April 7th. Piper Sandler reissued an “overweight” rating on shares of Stryker in a report on Tuesday, January 27th. Finally, Needham & Company LLC decreased their price target on shares of Stryker from $454.00 to $418.00 and set a “buy” rating for the company in a report on Friday. Sixteen analysts have rated the stock with a Buy rating and six have given a Hold rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $395.48.

Stryker Price Performance

NYSE:SYK opened at $291.21 on Tuesday. The company has a debt-to-equity ratio of 0.62, a current ratio of 2.11 and a quick ratio of 1.25. The firm has a market cap of $111.53 billion, a price-to-earnings ratio of 33.70, a price-to-earnings-growth ratio of 1.73 and a beta of 0.80. The company has a 50 day moving average price of $345.67 and a 200-day moving average price of $356.80. Stryker Corporation has a 1-year low of $290.22 and a 1-year high of $404.87.

Stryker (NYSE:SYK) last posted its earnings results on Thursday, April 30th. The medical technology company reported $2.60 earnings per share for the quarter, missing the consensus estimate of $2.98 by ($0.38). The firm had revenue of $6.02 billion for the quarter, compared to analysts’ expectations of $6.34 billion. Stryker had a net margin of 13.20% and a return on equity of 23.42%. Stryker’s revenue for the quarter was up 2.6% compared to the same quarter last year. During the same period last year, the firm earned $2.84 earnings per share. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. Equities research analysts forecast that Stryker Corporation will post 14.89 EPS for the current year.

Stryker Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Thursday, April 30th. Stockholders of record on Tuesday, March 31st were issued a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a dividend yield of 1.2%. The ex-dividend date of this dividend was Tuesday, March 31st. Stryker’s payout ratio is 40.74%.

Stryker Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.